Skip to main content
. 2016 Nov 16;7(52):86339–86349. doi: 10.18632/oncotarget.13404

Table 3. Composition of the prognosis tissue microarray containing 12,427 prostate cancer specimens.

No. of patients (%)
Study cohort on TMA Biochemical relapse among categories
(n = 12427)
Follow-up (mo)
n 11665 (93.9%) 2769 (23.7%)
Mean 48.9
Median 36.4
Age (y)
≤ 50 334 (2.7%) 81 (24.3%)
51–59 3061 (24.8%) 705 (23.0%)
60–69 7188 (58.2%) 1610 (22.4%)
≥ 70 1761 (14.3%) 370 (21.0%)
Pretreatment PSA (ng/ml)
< 4 1585 (12.9%) 242 (15.3%)
4–10 7480 (60.9%) 1355 (18.1%)
10–20 2412 (19.6%) 737 (30.6%)
> 20 812 (6.6%) 397 (48.9%)
pT category (AJCC 2002)
pT2 8187 (66.2%) 1095 (13.4%)
pT3a 2660 (21.5%) 817 (30.7%)
pT3b 1465 (11.8%) 796 (54.3%)
pT4 63 (0.5%) 51 (81.0%)
Gleason grade
≤ 3+3 2983 (24.1%) 368 (12.3%)
3+4 6945 (56.2%) 1289 (18.6%)
4+3 1848 (15.0%) 788 (42.6%)
≥ 4+4 584 (4.7%) 311 (53.3%)
pN category
pN0 6970 (91.0%) 1636 (23.5%)
pN+ 693 (9.0%) 393 (56.7%)
Surgical margin
Negative 9990 (81.9%) 1848 (18.5%)
Positive 2211 (18.1%) 853 (38.6%)

NOTE: Numbers do not always add up to 12,427 in the different categories because of cases with missing data. Abbreviation: AJCC, American Joint Committee on Cancer.